Magnesium has one primary role in cardiac arrest: treating a specific rhythm called torsades de pointes, a type of polymorphic ventricular tachycardia linked to a prolonged QT interval. Outside of that scenario, routine magnesium administration during cardiac arrest does not improve survival or neurological outcomes. Both the American Heart Association and the 2024 international resuscitation consensus are clear on this distinction.
The One Rhythm Where Magnesium Matters
Torsades de pointes is a distinctive, twisting pattern on a heart monitor where the electrical signal spirals in a way that prevents the heart from pumping effectively. It’s specifically tied to a prolonged QT interval, which reflects a delay in the heart’s electrical recharging cycle. When this rhythm causes cardiac arrest, magnesium is the go-to treatment.
The typical dose is 2 grams of magnesium sulfate given intravenously or through an intraosseous line, pushed over about 5 minutes during active resuscitation. In children, the dose is weight-based: 25 to 50 milligrams per kilogram, with a maximum of 2 grams. If the patient has a pulse but is in torsades, the infusion is given more slowly, over 10 to 20 minutes. Small case series have shown IV magnesium to be effective at suppressing and preventing recurrences of this rhythm.
One important distinction: polymorphic ventricular tachycardia with a normal QT interval is not the same thing as torsades de pointes, and magnesium is not recommended for it. The prolonged QT interval is the key identifier that makes magnesium appropriate.
Why Routine Use Doesn’t Help
For the more common cardiac arrest rhythms, including standard ventricular fibrillation and pulseless ventricular tachycardia, magnesium has been studied and found lacking. A randomized trial of 105 patients with refractory ventricular fibrillation (meaning the rhythm persisted after three defibrillation shocks) compared 2 to 4 grams of magnesium sulfate against placebo. Return of spontaneous circulation occurred in 17% of the magnesium group versus 13% of the placebo group, a difference that was not statistically significant. Survival to hospital discharge was similarly dismal in both groups: 4% versus 2%.
The 2024 International Liaison Committee on Resuscitation reviewed the accumulated evidence and concluded that giving magnesium during cardiac arrest did not improve return of spontaneous circulation, survival, or neurological outcomes regardless of the presenting rhythm. It also found no benefit for monomorphic ventricular tachycardia. Based on this, routine magnesium during cardiac arrest carries a “no benefit” classification in current guidelines.
Suspected Low Magnesium Levels
There is a secondary scenario where magnesium may be considered: when the arrest is suspected to stem from critically low magnesium levels. About 23% of cardiac arrest patients in one study were found to be hypomagnesemic on blood testing, though another 36% actually had elevated levels. Low magnesium can destabilize the heart’s electrical system in several ways, making it a plausible trigger for arrest in some patients.
Some prehospital protocols, including the 2025 Massachusetts statewide treatment protocols, include magnesium sulfate (2 to 4 grams IV over 5 minutes) for refractory ventricular fibrillation when hypomagnesemia is suspected. This reflects clinical pragmatism rather than strong trial evidence. If a patient has known risk factors for magnesium depletion (chronic diuretic use, alcoholism, prolonged vomiting or diarrhea), the clinical team may factor that into their decision.
How Magnesium Works in the Heart
Magnesium acts as the body’s natural calcium blocker inside heart muscle cells. During the electrical cycle that triggers each heartbeat, calcium floods into cells to cause contraction. Magnesium keeps that calcium influx in check, preventing the toxic overload that can drive dangerous rhythms. When magnesium is depleted, calcium flows in unchecked, and the heart’s electrical signals become unstable.
Magnesium also powers the sodium-potassium pump, the mechanism that resets each heart cell’s electrical charge between beats. Without enough magnesium, this pump slows down, leaving cells partially charged and prone to firing at the wrong time. This is why low magnesium doesn’t just cause one type of arrhythmia; it creates a generally unstable electrical environment that can tip into several dangerous rhythms, with torsades de pointes being the most directly responsive to magnesium replacement.
After the Heart Restarts
Once a patient regains a pulse, the question shifts to whether magnesium infusions help during post-resuscitation care. A study of in-hospital cardiac arrest found that empirical magnesium supplementation (a 2-gram bolus followed by 8 grams over 24 hours) did not improve resuscitation rates, 24-hour survival, or survival to hospital discharge.
However, a separate analysis of 438 cardiac arrest survivors who underwent therapeutic hypothermia (controlled cooling to protect the brain) found an interesting pattern. Lower magnesium levels at presentation and during cooling were associated with better outcomes, yet magnesium supplementation during the hospital stay was linked to improved neurological recovery. This suggests magnesium may play a supportive role alongside cooling protocols, though this hasn’t been formalized into treatment guidelines.
Quick Reference for Cardiac Arrest Rhythms
- Torsades de pointes (polymorphic VT with long QT): Magnesium is indicated. Give 2 g IV/IO bolus over 5 minutes during pulseless arrest, or over 10 to 20 minutes if a pulse is present.
- Polymorphic VT with normal QT: Magnesium is not recommended.
- Ventricular fibrillation or pulseless VT: Magnesium is not routinely recommended. May be considered if hypomagnesemia is suspected.
- Monomorphic VT: Magnesium has not shown benefit.
- Pulseless electrical activity or asystole: Magnesium is not part of standard treatment.